Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 8/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11304563 | 0.81 | RHEB (0.50) | HTR1BHTR1ACYP1A2CYP3A4LMNA | |
| SCHEMBL3794323 | 0.77 | HTR1B (0.55) | HTR1BHTR1ACYP1A2CYP3A4LMNA | |
| SCHEMBL29992666 | 0.75 | RHEB (0.45) | HTR1BHTR1ACYP1A2CYP3A4LMNA | |
| SCHEMBL3034603 | 0.75 | RHEB (0.45) | HTR1BHTR1ACYP1A2CYP3A4LMNA | |
| SCHEMBL15951727 | 0.75 | HTR1A (0.51) | HTR1BHTR1ACYP1A2CYP3A4LMNA | |
| SCHEMBL502401 | 0.75 | HTR1B (0.52) | HTR1BHTR1ACYP1A2CYP3A4LMNA | |
| SCHEMBL7084585 | 0.75 | HTR1B (0.52) | HTR1BHTR1ACYP1A2CYP3A4LMNA | |
| SCHEMBL8723087 | 0.75 | HTR1A (0.55) | HTR1BHTR1ACYP1A2CYP3A4LMNA | |
| SCHEMBL29445066 | 0.74 | RHEB (0.54) | HTR1BHTR1ACYP1A2CYP3A4LMNA | |
| SCHEMBL321761 | 0.74 | RHEB (0.54) | HTR1BHTR1ACYP1A2CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716493-B2 | Multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2066324-B1 | CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON INC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | CEPHALON, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2066324-A2 | CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON, INC. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| WO-2007149451-A2 | CYCLOALKANOPYRROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | MLKL, PARP3, PARP1 | HTR1B 1378/4885HTR1A 1497/4885CYP1A2 2301/4885 |
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | HTR1B 3231/4885HTR1A 3647/4885CYP1A2 1832/4885 |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | MLKL, PARP3, PARP1 | HTR1B 1378/4885HTR1A 1497/4885CYP1A2 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.